Search

Displaying results 8491 - 8500 of 10000 in total
  1. Drug

    Briquilimab

    go.drugbank.com/drugs/DB18136
    Investigational

    Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).

  2. Drug

    MTL-CEBPA

    go.drugbank.com/drugs/DB18143
    Investigational

    MTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.

  3. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  4. Drug

    Etavopivat

    go.drugbank.com/drugs/DB18176
    Investigational

    Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.

  5. Drug

    LYT-200

    go.drugbank.com/drugs/DB18179
    Investigational

    LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.

  6. Drug

    ATI-1013

    go.drugbank.com/drugs/DB18185
    Investigational

    ATI-1013 is a fully human nicotine-specific monoclonal antibody.

  7. Drug

    CLBS12

    go.drugbank.com/drugs/DB18192
    Investigational

    CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.

  8. Drug

    GX-G8

    go.drugbank.com/drugs/DB18196
    Experimental

    GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.

  9. Drug

    ST-003

    go.drugbank.com/drugs/DB18197
    Experimental

    ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.

  10. Drug

    FCX-013

    go.drugbank.com/drugs/DB18218
    Investigational

    FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).